Natera, Inc. (NASDAQ:NTRA) Shares Acquired by WCM Investment Management LLC

WCM Investment Management LLC increased its position in Natera, Inc. (NASDAQ:NTRAFree Report) by 101.2% in the fourth quarter, Holdings Channel reports. The firm owned 145,996 shares of the medical research company’s stock after purchasing an additional 73,419 shares during the quarter. WCM Investment Management LLC’s holdings in Natera were worth $9,058,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NTRA. Fifth Third Bancorp grew its position in shares of Natera by 3.0% in the 4th quarter. Fifth Third Bancorp now owns 6,216 shares of the medical research company’s stock worth $389,000 after acquiring an additional 179 shares in the last quarter. Treasurer of the State of North Carolina lifted its stake in Natera by 0.5% during the third quarter. Treasurer of the State of North Carolina now owns 45,469 shares of the medical research company’s stock worth $2,012,000 after purchasing an additional 230 shares during the last quarter. Royal Bank of Canada boosted its holdings in Natera by 0.3% in the third quarter. Royal Bank of Canada now owns 83,843 shares of the medical research company’s stock worth $3,710,000 after purchasing an additional 245 shares during the period. Xponance Inc. increased its stake in Natera by 1.8% during the third quarter. Xponance Inc. now owns 14,506 shares of the medical research company’s stock valued at $642,000 after purchasing an additional 261 shares during the last quarter. Finally, Public Employees Retirement System of Ohio raised its holdings in shares of Natera by 0.8% during the third quarter. Public Employees Retirement System of Ohio now owns 43,299 shares of the medical research company’s stock worth $1,897,000 after purchasing an additional 341 shares during the period. 99.90% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, insider Jonathan Sheena sold 26,700 shares of the firm’s stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $92.47, for a total transaction of $2,468,949.00. Following the completion of the sale, the insider now directly owns 321,031 shares in the company, valued at $29,685,736.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Jonathan Sheena sold 26,700 shares of the stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $92.47, for a total value of $2,468,949.00. Following the completion of the transaction, the insider now owns 321,031 shares in the company, valued at approximately $29,685,736.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael Burkes Brophy sold 1,378 shares of the business’s stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $92.62, for a total value of $127,630.36. Following the sale, the chief financial officer now owns 70,646 shares in the company, valued at approximately $6,543,232.52. The disclosure for this sale can be found here. Insiders have sold 366,477 shares of company stock worth $28,552,682 in the last ninety days. 9.42% of the stock is currently owned by corporate insiders.

Natera Price Performance

NASDAQ NTRA traded down $2.24 on Friday, reaching $94.47. 959,947 shares of the stock traded hands, compared to its average volume of 1,413,546. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $98.82. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37. The firm’s fifty day simple moving average is $84.14 and its 200 day simple moving average is $64.47. The company has a market cap of $11.41 billion, a price-to-earnings ratio of -24.93 and a beta of 1.37.

Natera (NASDAQ:NTRAGet Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The firm had revenue of $311.11 million for the quarter, compared to analysts’ expectations of $300.38 million. As a group, research analysts predict that Natera, Inc. will post -2.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on NTRA shares. Craig Hallum assumed coverage on shares of Natera in a research report on Monday, April 8th. They set a “buy” rating and a $117.00 price objective for the company. Canaccord Genuity Group raised their price target on Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, February 29th. BTIG Research upped their price objective on Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a research note on Friday, December 29th. Sanford C. Bernstein upgraded Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price on the stock in a research note on Friday, April 5th. Finally, Stephens restated an “overweight” rating and set a $78.00 price target on shares of Natera in a research report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and an average target price of $85.73.

Check Out Our Latest Report on Natera

Natera Company Profile

(Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

See Also

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRAFree Report).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.